VAXCYTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
VAXCYTE, INC. (PCVX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 29.64 thousand shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-05-06
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 29.64K shares, a 0.00% change year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 0.00 shares.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 29.64K shares, a 0.00% change year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 29.64K shares.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 36.71K shares.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 62.38K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | 29.64K shares 10-Q · filed 2026-05-06 | ||||
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-04 | 29.64K shares 10-Q · filed 2025-11-04 | 29.64K shares derived: sum of 4 quarters · filed 2025-11-04 | |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 29.64K shares 10-Q · filed 2025-08-06 | 29.64K shares derived: sum of 3 quarters · filed 2025-08-06 | 29.64K shares derived: sum of 4 quarters · filed 2025-08-06 | |
| 2025-03-31 | 29.64K shares 10-Q · filed 2025-05-07 | 29.64K shares derived: sum of 2 quarters · filed 2025-05-07 | 29.64K shares derived: sum of 3 quarters · filed 2025-05-07 | 29.64K shares derived: sum of 4 quarters · filed 2025-05-07 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | 0.00 shares derived: sum of 2 quarters · filed 2025-02-25 | 0.00 shares derived: sum of 3 quarters · filed 2025-02-25 | 29.64K shares 10-K · filed 2025-02-25 | |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 0.00 shares derived: sum of 2 quarters · filed 2024-11-05 | 29.64K shares 10-Q · filed 2024-11-05 | -7.07K shares derived: sum of 4 quarters · filed 2025-02-25 | |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 29.64K shares 10-Q · filed 2024-08-06 | -7.07K shares derived: sum of 3 quarters · filed 2025-02-25 | -7.07K shares derived: sum of 4 quarters · filed 2025-02-25 | |
| 2024-03-31 | 29.64K shares 10-Q · filed 2024-05-08 | -7.07K shares derived: sum of 2 quarters · filed 2025-02-25 | -7.07K shares derived: sum of 3 quarters · filed 2025-02-25 | -7.07K shares derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-12-31 | -36.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -36.71K shares derived: sum of 2 quarters · filed 2025-02-25 | -36.71K shares derived: sum of 3 quarters · filed 2025-02-25 | 0.00 shares 10-K · filed 2025-02-25 | 36.71K shares 10-K · filed 2024-02-27 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-06 | 36.71K shares 10-Q · filed 2023-11-06 | 11.04K shares derived: sum of 4 quarters · filed 2023-11-06 | |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 36.71K shares 10-Q · filed 2023-08-08 | 11.04K shares derived: sum of 3 quarters · filed 2023-08-08 | 11.04K shares derived: sum of 4 quarters · filed 2023-08-08 | |
| 2023-03-31 | 36.71K shares 10-Q · filed 2023-05-08 | 11.04K shares derived: sum of 2 quarters · filed 2023-05-08 | 11.04K shares derived: sum of 3 quarters · filed 2023-05-08 | 11.04K shares derived: sum of 4 quarters · filed 2023-05-08 | |
| 2022-12-31 | -25.67K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -25.67K shares derived: sum of 2 quarters · filed 2023-02-27 | -25.67K shares derived: sum of 3 quarters · filed 2023-02-27 | 36.71K shares 10-K · filed 2023-02-27 | |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 0.00 shares derived: sum of 2 quarters · filed 2022-11-07 | 62.38K shares 10-Q · filed 2022-11-07 | ||
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 62.38K shares 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | 62.38K shares 10-Q · filed 2022-05-09 | ||||
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -4.60K shares derived: sum of 2 quarters · filed 2021-11-10 | 62.38K shares 10-Q · filed 2021-11-10 | 57.78K shares derived: sum of 4 quarters · filed 2022-02-28 | |
| 2021-06-30 | -4.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | 62.38K shares 10-Q · filed 2021-08-11 | 57.78K shares derived: sum of 3 quarters · filed 2022-02-28 | 57.78K shares derived: sum of 4 quarters · filed 2022-02-28 | |
| 2021-03-31 | 66.98K shares 10-Q · filed 2021-05-11 | 62.38K shares derived: sum of 2 quarters · filed 2022-02-28 | 62.38K shares derived: sum of 3 quarters · filed 2022-02-28 | ||
| 2020-12-31 | -4.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -4.60K shares derived: sum of 2 quarters · filed 2022-02-28 | 62.38K shares 10-K · filed 2022-02-28 | 66.98K shares 10-K · filed 2021-03-29 | |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | 66.98K shares 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | 66.98K shares 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |